Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals
about
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor VaccinationRNA-Based Vaccines in Cancer ImmunotherapyRecombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapyDendritic cell-based human immunodeficiency virus vaccine.Developing mRNA-vaccine technologies.Mutant MHC class II epitopes drive therapeutic immune responses to cancer.CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer ImmunotherapySelective activation of trophoblast-specific PLAC1 in breast cancer by CCAAT/enhancer-binding protein beta (C/EBPbeta) isoform 2.Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugsParadigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.mRNA-based dendritic cell vaccines.The use of signal peptide domains as vaccine candidatesLuciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.mRNA Cancer Vaccines-Messages that Prevail.Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients.The European Regulatory Environment of RNA-Based Vaccines.Targeting the tumor mutanome for personalized vaccination therapy.CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic Cells.Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice.Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma
P2860
Q26769044-6F34FA07-11DC-43F5-8F5E-F3F1718410B0Q26776028-1D57DC50-B61A-4502-9FEB-544813D6CB59Q26861563-6257A8F4-ADE8-4A1C-8437-4B36DB52A49BQ28005535-5904ADCB-BE24-4A36-8BD5-12018A5BCE93Q33874652-3BF21F4F-040D-4BAE-8661-628CC49F7FD2Q36684597-E26356EC-FA1E-47BF-8536-5F0A74F4CA04Q36817092-0C650887-A8DE-41DD-84E3-5510541039DAQ37130209-6E29DE21-8149-43F4-9E45-268426688A98Q37431092-A5CA007C-4DE4-41CA-8230-D48F91EC5ADDQ37762274-EEB06A73-EF30-4C46-AA18-BA2AA5E29966Q38206520-D1189245-B0F4-4BCD-ADA4-3993E223FEA9Q38208309-774827B1-A2CB-4146-B267-3E36510F982AQ38246769-08F9C6E1-CCFF-48A1-9A69-93486EAD6981Q38284668-9E3F9B7A-6AC4-43ED-8747-D58176459552Q38779887-13DC898C-788A-4759-B466-71307F53C328Q39236800-21567171-4914-41A7-9401-A464690EA298Q39956346-5F7BF64C-700C-4ECB-A12C-D677FCDF1063Q40405913-52090940-E798-4E73-8270-4D0BDFD8ABAFQ41882039-74DF9164-4B87-46F5-9FC4-452C8B78F60CQ42586718-7CDDDBCD-2250-42EA-BDBD-DC1C52AED0CBQ45858586-79E71BAE-C4C2-431B-9BF2-DF41E15C835AQ45867833-DE6F03A7-CB53-4A2C-93CD-5E4B2406F35DQ51253901-3167081A-2A42-4A7A-B119-FB383822D4E7Q51313262-AC1936C5-B524-4D9E-864D-4D0CDE7BF939Q51638650-A338F52D-5F52-4100-9FB2-1678836B0D6CQ57221250-10D73126-5257-4DFA-B7C3-9A4FEB90B0C7
P2860
Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals
description
im Dezember 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 January 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2007
@uk
name
Increased Antigen Presentation ...... HC Class I Trafficking Signals
@en
Increased Antigen Presentation ...... HC Class I Trafficking Signals
@nl
type
label
Increased Antigen Presentation ...... HC Class I Trafficking Signals
@en
Increased Antigen Presentation ...... HC Class I Trafficking Signals
@nl
prefLabel
Increased Antigen Presentation ...... HC Class I Trafficking Signals
@en
Increased Antigen Presentation ...... HC Class I Trafficking Signals
@nl
P2093
P1476
Increased antigen presentation ...... HC class I trafficking signals
@en
P2093
Abderraouf Selmi
Christoph Huber
Hansjörg Schild
Martin Sebastian
Mustafa Diken
Ozlem Türeci
Phillip Osterloh
Sebastian Kreiter
P304
P356
10.4049/JIMMUNOL.180.1.309
P407
P50
P577
2008-01-01T00:00:00Z